SLC5A2 and type 2 diabetes mellitus: The findings guide the selection of SGLT-2 inhibitors for patients with T2DM based on the patient's profiles to maximize safety.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/prospero, identifier CRD42022334644.